Monthly Archives: August 2021

The One mRNA Vaccine Stock to Buy Today

Michael A. RobinsonMichael A. RobinsonMichael A. Robinson

For two months now, biotech companies have been talking about the eventual need for a coronavirus vaccine booster in at least some segments of the population.

Just this past weekend, the U.S. Food and Drug Administration recommended additional doses of the joint Pfizer Inc. (NYSE: PFE) and BioNTech SE ADR (NASDAQ: BNTX) vaccine and the Moderna Inc. (NASDAQ: MRNA) vaccine for some immunocompromised people.

Yesterday, sources inside the Biden administration told USA Today that the government is planning to recommend vaccine booster shots for all Americans no sooner than eight months after they received their second shot of either mRNA vaccine.

And of course, there are broadening vaccine “mandates,” too, all over the public and private sector, such as the Pentagon’s requirement that most of the country’s 1.3 million military personnel get vaccinated.

That puts the so-called “vaccine stocks” – the handful of biotech firms that developed effective coronavirus vaccines last year then skyrocketed accordingly – right back into play.

This time the game board is different. There’s the highly infectious SARS-CoV-2 B.1.617.2 “delta variant” to contend with, and the unsettling prospect of other, potentially more dangerous variants, too.

More importantly, there’s a different product pipeline now, and new applications for the vaccine technology that’s proven itself under fire and is on the way to becoming the new gold standard for many vaccines and therapies still on the way.

Conditions are looking good for another, potentially bigger round of profits for folks who buy the right vaccine stock, and I think one company looks better than the rest this time…

Make No Mistake: These Vaccines Are Effective

The media is full of reports of “breakthrough” COVID-19 infections in fully vaccinated individuals, but many lack the important context that puts breakthrough infections into perspective.

And that context is this…

The Wall Street Journal, analyzing reports from 45 state health departments, counted around 193,204 infections in vaccinated individuals between January and early August, 2021. Those infections represent just 0.1% – one-tenth of one percent – of the 136 million-plus vaccinated Americans. Less than 0.004% of those vaccinated folks with breakthroughs had to be hospitalized, and less than 0.001% of them died.

Anecdotally, on a personal note, I’ve had seven fully vaccinated friends come down with the coronavirus, but none of them were sick at all. One didn’t even know she had it until she got a positive result from a routine test.

So, while no vaccine on Earth is 100% effective against any virus, clearly, these vaccines are extremely effective at keeping people alive and out of the hospital, even accounting for delta variant infections.

A big reason for this effectiveness, not to mention the world-record speed at which they went from the drawing board into hundreds of millions of arms, is messenger RNA (mRNA) technology.

The Tech Behind the Vaccine “Moonshot”

Of the “Big Three” coronavirus vaccines currently authorized for use in the United States, two were developed using this new biotech – a completely new way of teaching the human body to fight off a virus that to date has infected at least 208 million people and killed at least 4.37 million of them.

I want to be absolutely clear: The vaccine doesn’t actually affect your body’s genetic code. Your DNA is unaffected.

Instead, these vaccines work using what’s called messenger RNA, or simply mRNA.

In short, when your cells create proteins out of their DNA, they don’t use the DNA directly. Instead, cells transcribe their DNA into RNA, a similar compound. The cell’s protein factories then translate the RNA into proteins, destroying the RNA in the process.

The mRNA vaccines use this process to, essentially, “trick” cells into creating specific proteins that make the cells look as if they have been infected by something – in this case, the SARS-C0V-2 “spike protein” the virus uses to infect cells.

But that’s an illusion. Your cells are perfectly healthy; your DNA never changes. What’s more, the mRNA in the vaccine degrades quickly, within a matter of days. Messenger RNA is extremely fragile, which is why the mRNA vaccines need to be kept at super-low temperatures.

The spike proteins generated by the COVID-19 vaccines last a few weeks, but very quickly, your immune system learns to identify, attack, and kill them. That’s a lesson the body remembers, so most folks’ immune systems will know how to identify, attack, and kill the real McCoy if or when the time comes.

This technology is a game changer – mRNA vaccines sidestep many of the concerns about vaccines that use live, inactive, or attenuated viruses or components of viruses, which in rare cases can infect the people they’re meant to protect.

They’re also much, much faster to produce at scale. Before mRNA vaccines, the Merck Mumpsvax mumps vaccine was the reigning “speed record holder” in the vaccine arena, and it took nearly four years to go from the drawing board to the market. And, as we all know, the first mRNA vaccines were being administered barely one year after SARS-CoV-2 emerged.

It’s thought that as many as 320,000 virus species can infect mammals, and as of today, science knows of around 219 species able to infect humans, from common colds to the deadly Ebola. There’s always a risk that a 220th will emerge to wreak havoc on society. Messenger RNA vaccine tech is humanity’s “ace in the hole” against an unwelcome development like that.

The COVID-19 pandemic lit a fire under the already promising field of mRNA vaccine research, but research into their use against influenza, rabies, Zika virus, and cytomegalovirus was far along when COVID-19 began to shut the world down in March 2020.

This Biotech Firm Was Always an mRNA Leader

Moderna was further along in its research than just about anyone else, but that’s not the only reason I’m recommending it today.

The company was founded in Cambridge, Massachusetts, in 2010 with the goal of commercializing mRNA technology. Moderna shares only listed in 2018, though, about two years before its breakthrough vaccine would make it a household name.

It was the focus on mRNA tech that enabled Moderna to pivot from its other avenues of research to COVID-19 so quickly.

But I don’t think people understand just how breathtakingly fast that pivot was…

Chinese scientists published the full genetic sequence of SARS-CoV-2 in early January of 2020. Moderna, which, as I said, was a leader in mRNA vaccine research, was first out the gate with a list of promising vaccine candidates – and a test dose of COVID-19 vaccine – just 63 days after the genetics information hit the Internet.

It’s true that the Pfizer-BioNTech partnership was first, by a week or so, to gain authorization for its mRNA vaccine, but its “edge” over Moderna in that one sense was limited, and investors clearly preferred Moderna, a fact that comes across when you compare stock charts for the past year.

moneymorning.com/wp-content/blogs.dir/1/files/2021/08/MRob818-2-300×261.png 300w, moneymorning.com/wp-content/blogs.dir/1/files/2021/08/MRob818-2-75×65.png 75w” data-lazy-sizes=”(max-width: 687px) 100vw, 687px” title=”” data-lazy-src=”https://moneymorning.com/wp-content/blogs.dir/1/files/2021/08/MRob818-2.png” />moneymorning.com/wp-content/blogs.dir/1/files/2021/08/MRob818-2-300×261.png 300w, moneymorning.com/wp-content/blogs.dir/1/files/2021/08/MRob818-2-75×65.png 75w” sizes=”(max-width: 687px) 100vw, 687px” title=”” />

Both mRNA vaccines are great, and one is about as effective as another, but it’s what’s coming next that’s likely to cement Moderna’s position as the vaccine stock to own.

As you read this, Moderna is hard at work developing 24 additional vaccine candidates – over and above its continuing research into the COVID-19 vaccine and how it could be tweaked to better ward off variants.

Among these candidates is an annual vaccine booster for 2023 and beyond. Existing flu vaccines are anywhere from 40% to 60% effective at preventing severe disease – this qualifies as “good” protection, but Moderna is working to move the needle into “Excellent” territory. The company is also working on vaccines for HIV and respiratory syncytial virus (RSV). RSV is coming back in force as societies reopen, and it’s beginning to show up out of season, too. The respiratory virus can seriously harm infants, toddlers, and the elderly.

Beyond the vaccine sphere, Moderna is developing 13 different mRNA treatments, including five for cancer; it has two autoimmune therapies in clinical trials at this point.

So Moderna is anything but a one-hit wonder whose stock has already “popped.” If, for whatever reason, you missed MRNA shares’ big rocket ride, there’s still much more to come.

This company has the kind of pipeline that can generate billions in sales over the next decade and beyond.

With all that said, it’s undeniable earnings growth over the last three years has been weak; the company has understandably plowed so much capital into R&D. But in the quarter ending in June, Moderna earned $6.46 per share compared with a year-ago loss and came on the back of a 6,400% sales increase.

Moderna also raised forecasts for the year. For 2022, it has already signed contracts to deliver $12 billion worth of COVID-19 vaccines. Not only that, but clients have options to purchase more doses worth roughly $8 billion.

To be conservative, let’s project that per-share profits average 25%. At that rate, earnings will double in about 33 months – and, being conservative, that doesn’t account for the likelihood of a Moderna breakthrough on any one of the several trials and lines of research it’s working on.

This progress isn’t happening in a vacuum. All over the world, but particularly here in the United States, we’re seeing an explosion in creativity. Whether it’s getting a lifesaving vaccine to market in record time, or delivering some other game-changing tech breakthrough, can-do spirit, good old-fashioned entrepreneurialism (and hundreds of billions of dollars in fresh capital since November 2020) are combining in an explosion of profit potential.

No wonder, then, that there are more than 500 private companies of all kinds looking to go public in the United States right now. This can be the best time to claim a stock in these companies using something called “pre-IPO rights.” It’s possible to claim these for $1 in many cases, but, should the company go public, these rights can have stratospheric profit potential – peak gains of 2,088%, 6,566%, 8,280%, 9,075%, even 27,550% have been realized in exceptional cases. You can learn some more about these remarkable instruments here…

Follow Money MorningonFacebook and Twitter.

Join the conversation. Click here to jump to comments…

Michael A. RobinsonMichael A. RobinsonMichael A. Robinson

About the Author

Browse Michael’s articles | View Michael’s research services

Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That’s because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley “insiders” right to you…

He was one of five people involved in early meetings for the $160 billion “cloud” computing phenomenon. He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry. As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.

This all means the entire world is constantly seeking Michael’s insight.

In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse – years before the word “bailout” became a household word.

Silicon Valley defense publications vie for his analysis. He’s worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.

And even with decades of experience, Michael believes there has never been a moment in time quite like this.

Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.

To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.

His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.

… Read full bio

Financial Contrast: Perella Weinberg Partners (NASDAQ:PWP) versus Franklin Resources (NYSE:BEN)

Perella Weinberg Partners (NASDAQ:PWP) and Franklin Resources (NYSE:BEN) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Earnings & Valuation

Get Perella Weinberg Partners alerts:

This table compares Perella Weinberg Partners and Franklin Resources’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Perella Weinberg Partners N/A N/A -$5.11 million N/A N/A
Franklin Resources $5.57 billion 2.80 $798.90 million $2.61 11.88

Franklin Resources has higher revenue and earnings than Perella Weinberg Partners.

Profitability

This table compares Perella Weinberg Partners and Franklin Resources’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Perella Weinberg Partners N/A N/A N/A
Franklin Resources 15.65% 13.73% 7.23%

Institutional & Insider Ownership

40.5% of Perella Weinberg Partners shares are owned by institutional investors. Comparatively, 42.4% of Franklin Resources shares are owned by institutional investors. 23.1% of Franklin Resources shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Perella Weinberg Partners and Franklin Resources, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perella Weinberg Partners 0 0 3 0 3.00
Franklin Resources 5 3 2 0 1.70

Perella Weinberg Partners presently has a consensus price target of $17.50, indicating a potential upside of 29.34%. Franklin Resources has a consensus price target of $26.20, indicating a potential downside of 15.51%. Given Perella Weinberg Partners’ stronger consensus rating and higher probable upside, equities analysts clearly believe Perella Weinberg Partners is more favorable than Franklin Resources.

Summary

Franklin Resources beats Perella Weinberg Partners on 7 of the 10 factors compared between the two stocks.

About Perella Weinberg Partners

Perella Weinberg Partners provides investment banking services worldwide. The company offers strategic, financial, and tactical advice services in connection with executing complex mergers, acquisitions, company sales, and corporate divestitures, including carve-outs, joint ventures, and spin-offs, as well as relating to takeover preparedness and defense. It serves corporations, institutions, governments, sovereign wealth funds, and private equity investors. The company is based in Philadelphia, Pennsylvania.

About Franklin Resources

Franklin Resources, Inc. is a holding company, which engages in the provision of investment management and related services. It offers its products and services under the brands of Franklin, Templeton, Franklin Mutual Series, Franklin Bissett, Fiduciary Trust, Darby, Balanced Equity Management, K2, LibertyShares, and Edinburgh Partners. The company was founded by Rupert H. Johnson, Jr. in 1947 and is headquartered in San Mateo, CA.

California Water’s (CWT) Investments, Rate Hikes Bode Well

tags:

California Water Service Group’s (CWT Quick QuoteCWT ) strategic acquisitions and investments to upgrade or replace its water infrastructure will help the utility serve its growing customer base efficiently. Also, rate hikes are aiding the company’s performance.

Tailwinds

With its focus on expanding operations in the Western United States, California Water Service continues to explore opportunities for extending its regulated and non-regulated water and wastewater activities. To this end, the utility invested $138.5 million in the first six months of 2021 after spending $298.7 million in 2020. Its capital expense estimate for 2021 is in the $270-$300 million range.    

The company is undertaking acquisitions and replacement projects to enhance the reliability of its services and broaden its business scope. Such efforts improved its customer base by 4.3% year over year in 2020. Other water utilities like American Water Works Co. (AWK Quick QuoteAWK ) , Middlesex Water (MSEX Quick QuoteMSEX ) and Essential Utilities (WTRG Quick QuoteWTRG ) are also investing heavily in bettering system reliability and efficiently serving their growing customer bases.

California Water Service has been benefiting from rate hikes since the beginning of 2014. The rate base is expected to improve from $1.82 billion in 2021 to $2.74 billion in 2025. The ongoing expansion of the rate base will positively impact its earnings over the long term.

The utility also boasts ample liquidity to meet its near-term obligations. As of Jun 30, it had $66.5 million of cash and additional current capacity of $405 million on the lines of credit, subject to meeting its borrowing conditions.

Woes

More than 93.8% of California Water Service’s operations is concentrated within the state itself, exposing it to various hazards. Its aging water infrastructure requires constant investments in maintaining the reliability of services. Moreover, the risk involving contaminati! on of water supplied by the company is a concern.

Zacks Rank & Price Performance

This currently Zacks Rank #2 (Buy) company has gained 37.2%, outperforming the industry’s rise of 16.9% in the past year. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

One-Year Price Performance

Zacks Investment Research
Image Source: Zacks Investment Research

Best Oil Stocks To Buy Right Now

Shares of Magnolia Oil & Gas Corporation (MGY Quick QuoteMGY ) stock has shown no substantial movement since second-quarter 2021 earnings announcement on Aug 2. In fact, the firm’s shares failed to display an uptrend despite impressive bottom-line and top-line performances as well as an upbeat third-quarter production guidance, which indicates growth from the sequential quarter’s reported figure.

Delving Deeper

The company reported second-quarter adjusted net income per share of 56 cents, beating the Zacks Consensus Estimate of 37 cents. The bottom line reversed the year-ago quarter’s loss of 8 cents per share.

This outperformance can be primarily attributed to better-than-anticipated production volumes. The South Texas-focused company’s average daily oil output of 31,897 barrels per day surpassed the Zacks Consensus Estimate of 30,734 barrels.

Total revenues came in at $250.73 million, ahead of the Zacks Consensus Estimate of $229 million. Moreover, the top line rose 202.7% from the year-ago level of $82.84 million.

Best Oil Stocks To Buy Right Now: Cheniere Energy, Inc.(LNG)

Cheniere Energy, Inc., incorporated on March 25, 1983, is an energy company primarily engaged in liquefied natural gas (LNG) related businesses. The Company operates through two segments: LNG terminal business and LNG and natural gas marketing business The Company owns and operates the Sabine Pass LNG terminal in Louisiana through its ownership interest in and management agreements with Cheniere Energy Partners, L.P. (Cheniere Partners), which is a publicly traded limited partnership. The Company owns approximately 100% of the general partner interest in Cheniere Partners and over 80% of Cheniere Energy Partners LP Holdings, LLC (Cheniere Holdings), which is a publicly traded limited liability company that owns approximately 56% limited partner interest in Cheniere Partners.

The Sabine Pass LNG terminal has operational regasification facilities owned by Cheniere Partners subsidiary, Sabine Pass LNG, L.P. (SPLNG) that includes existing infrastructure of over five LNG storage tanks with capacity of approximately 16.9 billion cubic feet equivalent (Bcfe), over two docks that can accommodate vessels with nominal capacity of approximately 266,000 cubic meters and vaporizers with regasification capacity of approximately 4.0 billion cubic feet per day (Bcf/d). Cheniere Partners is developing and constructing natural gas liquefaction facilities (Sabine Pass Liquefaction Project) at the Sabine Pass LNG terminal adjacent to the existing regasification facilities through a subsidiary, Sabine Pass Liquefaction, LLC (Sabine Pass Liquefaction). Cheniere Partners also owns a 94-mile pipeline that interconnects the Sabine Pass LNG terminal with a number of interstate pipelines (the Creole Trail Pipeline) through a subsidiary, Cheniere Creole Trail Pipeline, L.P. (CTPL).

The Company is developing and constructing a second natural gas liquefaction and export facility at the Corpus Christi LNG terminal, which is on over 2,000 acres of land that it owns or controls near Corpus Christi, Texas,! and a pipeline facility (the CCL Project) through its subsidiaries Corpus Christi Liquefaction, LLC (CCL) and Cheniere Corpus Christi Pipeline, L.P. (CCP), respectively. The CCL Project also includes a 23-mile, 48-inch natural gas supply pipeline that will interconnect the Corpus Christi LNG terminal with several interstate and intrastate natural gas pipelines (the Corpus Christi Pipeline). The Companys subsidiary, Cheniere Marketing, LLC (Cheniere Marketing), is engaged in the LNG and natural gas marketing business, and is developing a portfolio of long-term, short-term and spot LNG sale and purchase agreements (SPAs).

LNG Terminal Business

The Company is focused on the development of over two LNG terminal projects: the Sabine Pass LNG terminal in western Cameron Parish, Louisiana, less than four miles from the Gulf Coast on the Sabine-Neches Waterway and the Corpus Christi LNG terminal near Corpus Christi, Texas. Through Cheniere Partners, the Company has constructed and is operating regasification facilities at the Sabine Pass LNG terminal and are developing and constructing the Sabine Pass Liquefaction Project. It owns approximately 100% of the general partner interest in Cheniere Partners and over 80.1% of Cheniere Holdings, which owns approximately 55.9% limited partner interest in Cheniere Partners. The Company owns approximately 100% interest in the CCL Project. Sabine Pass Liquefaction has third-party SPAs, including BG Gulf Coast LNG, LLC (BG), Gas Natural Aprovisionamientos SDG S.A. (Gas Natural Fenosa), Korea Gas Corporation (KOGAS), GAIL (India) Limited (GAIL) and Centrica plc (Centrica). Corpus Christi Liquefaction’s third-party SPAs include Endesa Generacion, S.A., Iberdrola S.A., Gas Natural Fenosa LNG SL, Woodside Energy Trading Singapore Pte Ltd, PT Pertamina (Persero), Electricite de France, S.A. and EDP Energias de Portugal S.A.

LNG and Natural Gas Marketing Business

The Companys subsidiary, Cheniere Marketing, is engaged in ! the LNG a! nd natural gas marketing business and is developing a portfolio of long-term, short-term and spot LNG purchase and spot LNG SPAs. Cheniere Marketing purchases, transports and unloads commercial LNG cargoes into the Sabine Pass LNG terminal and other LNG terminals around the world.

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    He earned more than $100 million in a famous board room battle with RJR Nabisco, and recently he’s led the charge in pressing Caesars Entertainment Corp. (NASDAQ: CZR) to sell its assets. Rumors are swirling that the gambling giant will soon merge with Eldorado Resorts Inc. (NASDAQ: ERI). He also has stakes in CVR Energy Inc. (NYSE: CVI), Herbalife Nutrition Ltd. (NYSE: HLF), Cheniere Energy Inc. (NYSE: LNG), Newell Brands Inc. (NASDAQ: NWL), and of course, his firm Icahn Enterprises LP (NASDAQ: IEP).

  • [By Motley Fool Transcribers]

    Cheniere Energy Inc (NYSEMKT:LNG)Q42018 Earnings Conference CallFeb. 26, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Best Oil Stocks To Buy Right Now: Orocobre Limited (OROCF)

Orocobre Limited operates primarily in Argentina in the mining industry. The Company engages in the production ramp up of its Olaroz Lithium Facility and the operation of Borax Argentina S.A. (Borax Argentina). Its segments include Corporate, the Olaroz project, South American Salars and Borax Argentina. Its primary focus is on exploration for and development of lithium, potash and salar mineral deposits. The Company’s assets also include boron mines and processing facilities of Borax Argentina and a portfolio of brine exploration projects. Its Olaroz Lithium Facility is located in the Puna region of Jujuy Province in northern Argentina, over 230 kilometers northwest of the capital city of Jujuy. Borax Argentina operates over three open pit mines in Tincalayu, Sijes and Porvenir. Borax Argentina produces products, including minerals, such as ulexite, colemanite and hydroboracite; refined products, such as borax decahydrate, borax pentahydrate and borax anhydrous, and boric acid. Advisors’ Opinion:

  • [By ]

    In April 2018, Nemaska (OTCQX:NMKEF) drew nearly $100 million in investment from Japan’s SoftBank (OTCPK:SFTBY) group in exchange for a 9.9% interest in the company and access to lithium hydroxide produced by the company. In March 2018, CATL the world’s soon-to-be largest lithium battery manufacturer purchased a controlling stake in the Quebec Lithium project in consideration for $66 million. In February 2018, Korean steel giant, POSCO (PKX) announced a supply agreement and investment into Australian lithium miner Pilbara Minerals (OTCPK:PILBF). In January 2018, Toyota Tsusho (OTCPK:TYHOF), the strategic trading arm of Toyota Motors, invested approximately A$300 million in Orocobre (OTCPK:OROCF) in consideration for 15% of the company. Now, in April 2018, Swedish battery start-up NorthVolt has announced that it has signed an agreement for the supply of up to 5,000 metric tons per year of lithium hydroxide produced at Nemaska Lithium’s commercial plant in Shawinigan, Quebec. In connection with the supply of lithium chemicals, NorthVolt has agreed to deliver to Nemaska a 10 million euro promissory note that can be converted into voting shares of NorthVolt.

  • [By ]

    Early-stage lithium producer Orocobre (OTCPK:OROCF) has been busy developing its Argentine flag-ship asset at Olaroz. The company has managed to scale up the asset to around 12,000 T / year LCE with a nameplate production capacity of 17,500 T / year. Although the company has not achieved full production capacity at its asset, it has moved ahead with joint venture partner Toyota Tsusho (OTCPK:TYHOF) to develop plans for Phase 2. In January 2018, Orocobre announced that Toyota Tsusho would invest nearly $300 million for a 15% stake in the company, along with plans to double production capacity at Olaroz to 42,000 T LCE / year. The joint venture is also building a lithium hydroxide facility in Japan which will supply the local battery supply chain.

Best Oil Stocks To Buy Right Now: Impax Laboratories, Inc.(IPXL)

Impax Laboratories, Inc., incorporated on March 23, 1995, is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. The Company’s segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of the Company’s generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Impax Generics

The Company is focused on developing, manufacturing, selling and distributing solid dose and alternative dosage form products covering a range of therapeutic areas and drug-delivery mechanisms or product development formulations. The Company also develops, manufactures, sells and distributes specialty generic pharmaceuticals. It sells and distributes generic pharmaceutical products through over four sales channels, such as the Impax Generics sales channel, which includes generic pharmaceutical prescription products it sells directly to wholesalers, retail drug chains and others; Rx Partner sales channel, which includes generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance and collaboration agreements; Private Label sales channel, which includes generic pharmaceutical over-the-counter (OTC) and prescription products it sells to unrelated third parties and in-turn sells the product under t! heir own label, and OTC Partner sales channel, which includes sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical companies pursuant to alliance, collaboration and supply agreements. The Company markets over 140 generic pharmaceutical products representing dosage variations of approximately 60 different pharmaceutical compounds through its Impax Generics, and over five other generic pharmaceutical products, representing dosage variations of approximately two different pharmaceutical compounds, through its alliance and collaboration agreement partners.

Impax Specialty Pharma

The Impax Specialty Pharma segment is focused on the development and promotion through its specialty sales force of branded pharmaceutical products for the treatment of central nervous system (CNS) disorders, which include migraine, multiple sclerosis, PD and postherpetic neuralgia. The Company’s branded pharmaceutical product portfolio consists of commercial CNS products and development stage projects. The Impax Specialty Pharma segment is also engaged in the sale and distribution of over four other branded products, including Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches, and Albenza, indicated for the treatment of tapeworm infections.

The Company competes with Teva Pharmaceutical Industries Ltd., Allergan Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lannett Company, Inc., Lupin Pharmaceuticals, Inc., Endo International plc and Sandoz.

Advisors’ Opinion:

  • [By Max Byerly]

    News articles about Impax Laboratories (NASDAQ:IPXL) have trended somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Impax Laboratories earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 43.4189030940397 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Schnitzer Steel Agrees to Buy Columbus Recycling Assets

Schnitzer Steel (SCHN) – Get Report shares fell Tuesday, after the recycled metal maker announced an agreement to buy assets from Columbus Recycling in the Southeast. Financial terms weren’t disclosed. Columbus Recycling provides metal recycling products and services. Purchasers in corporate acquisitions often see their stock price fall because of the money that have to shell out in the deal. Portland-based Schnitzer on Tuesday traded at $52.04, down 3%. TheStreet RecommendsPRESS RELEASESBevCanna Announces Product Listings And Purchase Orders From Alberta Gaming And Liquor Commission29 minutes agoPRESS RELEASESSurgical Simulation Market To Reach $1,643.7 Million By 2030 Says P&S Intelligence29 minutes agoPRESS RELEASESPersonnel Boost At Bullfinch44 minutes ago Schnitzer agreed to acquire eight of Columbus’ operating facilities in Mississippi, Tennessee, and Kentucky. The transaction is expected to close during the first quarter of Schnitzer’s 2022 fiscal year, subject to regulatory approvals. Founded in 1956, Columbus Recycling purchases and processes scrap metal from industrial manufacturers, local recycling companies and individuals, and sells the recycled products to regional foundries and steel mills. “Combined with Schnitzer’s nine existing facilities in Georgia, Alabama, and Tennessee, the acquired operations will offer additional recycling products, services, and logistics solutions to customers and suppliers across the Southeast, a region that is expected to see a significant increase in electric arc furnace steelmaking capacity in the coming years,” Schnitzer said. In the 12 months through May, Columbus registered sales volumes of approximately 300,000 ferrous tons, which, on a pro-forma basis, would increase Schnitzer’s total ferrous volumes by approximately 7% over the same period, Schnitzer said. It also announced the successful restart of production at its Cascade Steel Rolling Mills in McMinnville, Ore. Earlier this week, Cascade restarted production after replacement and repairs of property and equipment at the mill’s melt shop that had been lost or damaged by a fire on May 22.